Bicara Therapeutics Inc. (NASDAQ: BCAX) reported preliminary data from a Phase 1b expansion cohort evaluating 750 mg of ficerafusp alfa ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE